Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk

Abstract
The high-risk pedigree (HRP) design is an established strategy to discover rare, highly-penetrant, Mendelian-like causal variants. Its success, however, in complex traits has been modest, largely due to challenges of genetic heterogeneity and complex inheritance models. We describe a HRP strategy that addresses intra-familial heterogeneity, and identifies inherited segments important for mapping regulatory risk. We apply this new Shared Genomic Segment (SGS) method in 11 extended, Utah, multiple myeloma (MM) HRPs, and subsequent exome sequencing in SGS regions of interest in 1063 MM / MGUS (monoclonal gammopathy of undetermined significance–a precursor to MM) cases and 964 controls from a jointly-called collaborative resource, including cases from the initial 11 HRPs. One genome-wide significant 1.8 Mb shared segment was found at 6q16. Exome sequencing in this region revealed predicted deleterious variants in USP45 (p.Gln691* and p.Gln621Glu), a gene known to influence DNA repair through endonuclease regulation. Additionally, a 1.2 Mb segment at 1p36.11 is inherited in two Utah HRPs, with coding variants identified in ARID1A (p.Ser90Gly and p.Met890Val), a key gene in the SWI/SNF chromatin remodeling complex. Our results provide compelling statistical and genetic evidence for segregating risk variants for MM. In addition, we demonstrate a novel strategy to use large HRPs for risk-variant discovery more generally in complex traits. Although family-based studies demonstrate inherited variants play a role in many common and complex diseases, finding the genes responsible remains a challenge. High-risk pedigrees, or families with more disease than expected by chance, have aided discovery of genes responsible for less complex diseases, but high-risk pedigrees have not reached their potential in complex diseases. Here, we describe a method to utilize high-risk pedigrees to discover risk-genes in complex diseases. Our method is appropriate for complex diseases because it allows for genetic-heterogeneity, or multiple causes of disease, within a pedigree. This method allows us to identify shared segments that likely harbor disease-causing genes in a family. We apply our method in Myeloma, a heritable and complex cancer of plasma cells. We identified two genes USP45 and ARID1A that fall within shared segments with compelling statistical evidence. Exome sequencing of these genes revealed likely-damaging variants inherited in Myeloma high-risk families, suggesting these genes likely play a role in development of Myeloma. Our Myeloma findings demonstrate our high-risk pedigree method can identify genetic regions of interest in large high-risk pedigrees that are also relevant to smaller nuclear families and overall disease risk. In sum, we offer a strategy, applicable across phenotypes, to revitalize high-risk pedigrees in the discovery of the genetic basis of common and complex disease.
Funding Information
  • Utah Genome Project
  • Utah Hematology Disease Oriented Team
  • National Institutes of Health (R01 CA134674)
  • National Institutes of Health (R01 CA163353)
  • National Institutes of Health (R01 CA168762)
  • National Institutes of Health (R01 CA107476)
  • National Institutes of Health (R01 MH094400)
  • National Institutes of Health (R01 MH099134)
  • National Institutes of Health (R01 CA167824)
  • National Institutes of Health (R01 DK091374)
  • National Institutes of Health (R01 DK093151)
  • National Institutes of Health (R21 CA152336)
  • National Institutes of Health (R21 CA191896)
  • National Institutes of Health (S10OD018522)
  • National Institutes of Health (T15-LM-007124)
  • National Institutes of Health (P30 CA42014)
  • National Institutes of Health (HHSN261201000026C)
  • Utah Department of Health
  • University of Utah
  • Leukemia and Lymphoma Society (6067-09)
  • National Center for Advancing Translational Sciences (UL1TR001067)